Trials / Completed
CompletedNCT04518995
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 706 (actual)
- Sponsor
- Concert Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-543 matching placebo | Administered as tablets. |
| DRUG | CTP-543 | Administered as tablets. |
| DRUG | CTP-543 | Administered as tablets. |
Timeline
- Start date
- 2020-11-23
- Primary completion
- 2022-04-19
- Completion
- 2022-04-19
- First posted
- 2020-08-19
- Last updated
- 2023-05-03
- Results posted
- 2023-05-03
Locations
72 sites across 5 countries: United States, Canada, France, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04518995. Inclusion in this directory is not an endorsement.